Yuanyan Yaogang Biopharmaceutical (Shenyang) Joint-Stock Co., Ltd.

Yuanyan Yaogang Biopharmaceutical (Shenyang) Joint-Stock Co., Ltd. was established on August 9, 2004. Its registered and production address is No. 176, Shenbei Road, Huishan Economic Development Zone, Shenbei New District, Shenyang. The company type is a limited liability company. The production scope includes small-volume injections, lyophilized powder injections, APIs, tablets, hard capsules, etc.; pharmaceutical research and technology transfer; and food production and sales.

The company covers an area of more than 20,000 square meters, of which the main building area is 8,000 square meters, including an office and laboratory building of over 3,000 square meters, and a production workshop of 5,000 square meters, comprising injection production lines, solid preparation production lines, oral liquid and API production lines. Moreover, there is nearly 10,000 square meters of vacant land available for Phase II construction.

The company has eight functional departments: Production Department, Quality Department, Business Department, Materials Control Department, Finance Department, Administration and Human Resources Department, Equipment Department, and Medical Department. Professional and technical personnel account for 50% of the total employees, product R&D personnel account for 18.7%, and those with intermediate and senior professional titles account for 15.74% of the technical staff.

The injection workshop has a lyophilized powder injection production line with an annual capacity of approximately 15 million vials and a liquid injection production line with an annual capacity of approximately 20 million vials. Small-volume injections and lyophilized powder injections obtained the GMP certificate from the National Medical Products Administration in July 2006. The software and hardware facilities are fully suitable for large-scale production. The company currently routinely produces 9 injection varieties in 16 specifications, including Ozagrel Sodium for Injection, Adenosine Cyclophosphate for Injection, Clindamycin Phosphate Injection, Isosorbide Mononitrate Injection, Cytidine Disodium Triphosphate Injection, Lomefloxacin Aspartate Injection, Puerarin Injection, Ligustrazine Phosphate Injection, and Alprostadil for Injection.

The solid preparation production line has an annual tablet capacity of 180 million tablets (taking folic acid tablets as an example) and an annual capsule capacity of 80 million capsules. The solid preparation workshop passed GMP certification in March 2009 and has entered large-scale production. The company has 136 solid preparation specifications, with routine products including Folic Acid Tablets, Qinhuang Houzheng Capsules, Lappaconitine Hydrobromide Tablets, Benorilate Tablets, Licorzine Capsules, Ursodeoxycholic Acid Tablets, and Compound Methionine and Choline Tablets.

The oral liquid workshop has received an investment of 10 million RMB. The workshop has passed acceptance checks for fire protection and environmental protection, completed the purchase, installation, and commissioning of equipment and facilities, and personnel have been trained and stationed. The oral liquid workshop passed GMP certification in early 2011 and entered large-scale production. This workshop produces Xiaozheng Fuzheng Oral Liquid, with planned production capacity of 25,000 bottles in the first year, 170,000 bottles in the second year, and industrialization to 420,000 bottles in the third year.

The company has obtained clinical trial approval for the innovative drug Mildronate Injection (chemical drug class 3.1). Phase II clinical trials have been completed, and the company is currently preparing for production application. The company holds independent intellectual property rights for this product. Mildronate Injection is mainly used for cerebrovascular diseases such as cerebral ischemia, dementia, and peripheral blood flow disorders. It is an optimal drug for the treatment and adjuvant therapy of cardiovascular and cerebrovascular diseases, with very broad clinical application prospects. It is designated as the company's core product.

The traditional Chinese medicine product Xiaozheng Fuzheng Oral Liquid is an exclusive product of the company. A patent application is being filed with the State Intellectual Property Office. This product enhances the body's immune function, thereby effectively inhibiting and treating tumors. The company's oral liquid workshop has completed construction, passed GMP certification in early 2011, and entered large-scale production.

In response to the characteristics of different products and sales regions, the company adopts various sales operation models, such as clinical distribution supplemented by commercial allocation, logistics radiation, and direct sales in the third terminal.

For products subject to bidding and procurement, the company adopts a government procurement-oriented approach. For example, Folic Acid Tablets fully leverage the "Folic Acid for All" concept, effectively supplementing the free market in townships, focusing on occupying urban markets, strengthening terminal promotion, and exploring distribution and sales policies for key regions and key customers when necessary.

The company passed ISO environmental management system and quality management system certifications in July 2010 and has successively been awarded the title of "Abiding by Contracts and Valuing Credit" by provincial and municipal industry and commerce departments. To fully and effectively implement GMP management, combined with the company's specific processes and actual product conditions, the company has established a comprehensive and effective production management and quality management system, managing and controlling the entire production process. From supplier audits of raw materials to incoming inspection, from production process control to finished product release, each link is strictly controlled. To ensure product quality, each position is staffed with highly qualified management and technical personnel.

Yuanyan Yaogang Biopharmaceutical (Shenyang) Joint-Stock Co., Ltd. strives to enter the high-tech field of the pharmaceutical industry. Within the Huishan Economic Development Zone of Shenbei New District, it aims to establish a production enterprise with domestically advanced standards and international integration, following modern enterprise operation models with modernized production and scientific management. Adhering to the tenet of "High-Quality Pharmaceuticals, Utmost Sincerity in Service," the company leverages its strong talent and technological advantages to continuously develop new products and markets, dedicated to the growth of the pharmaceutical industry and serving human health.